Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline.
Since the introduction of clotting factor concentrates, life expectancy of haemophilia patients is increasing and now approaches that of the general male population. Increasingly, haemophilia patients are confronted with age-related co-morbidity, including ischaemic cardiovascular disease. Treatment of stable angina pectoris and the acute coronary syndrome with antithrombotic therapy and percutaneous coronary intervention in haemophilia patients is feasible, but requires a tight co-operation between all specialists involved. As evidence-based guidelines are lacking, we developed a protocol on how we will treat haemophilia patients with ischaemic heart disease.
Schutgens
R E G
RE
Van Creveldkliniek/Department of Haematology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, Utrecht 3508 GA, The Netherlands. r.schutgens@umcutrecht.nl
Tuinenburg
A
A
Roosendaal
G
G
Guyomi
S Hoseyni
SH
Mauser-Bunschoten
E P
EP
D054058:Acute Coronary Syndrome / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D015906:Angioplasty, Balloon, Coronary; D002985:Clinical Protocols; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006467:Hemophilia A / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000235:genetics / Q000601:surgery*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D015607:Stents
D005343:Fibrinolytic Agents